

### **VaRi Bioscience GmbH announces initiation of development and expansion of respective IPR portfolio**

Berlin, Germany, 08. November 2021 - VaRi Bioscience GmbH ("VaRi"), an innovative biotech company founded in 2021 in Berlin focusing on novel drug delivery approaches in Female Health, announced today that it has started development activities for their vaginal ring products VR101 and VR102 together with its partners. The joint development strategy aims to deliver novel products in areas of high unmet medical need, such as, e.g., contraception for a growing patient subpopulation (VR101), and menopause management (VR102). Both products will be applied by convenient administration routes using proprietary and easy-to-use vaginal ring concepts.

As the API used in the VR101 vaginal ring product is commercially not available, it will be produced at VaRi's development and CDMO partner. Orlin Petrov, Ph.D., Head of Chemical Development at VaRi Bioscience, comments: "We are delighted that our novel route scouting activities have proven to be successful in various regards. The new synthetic route is shorter and easier to scale-up. Subsequently, it has the potential to speed up API delivery and reduces cost of goods significantly".

At the same time, GMP drug substance supply has been secured and triggered experimental work on vaginal ring development for VR102. "The trustful collaboration between us and our external partners enabled the initiation of development work on both projects ahead of projected timelines and is now performed at full speed." explained Klaus Nickisch, Ph.D., Chief Executive Officer of VaRi Bioscience.

In order to secure a strong IPR and FTO position, patent applications for both vaginal ring products, VR101 and VR102, will be filed before the end of this month. "We are confident that the two patent applications will form the basis for a strong intellectual patent portfolio protecting both projects from generic competition for many years". said Klaus Nickisch, Ph.D., Chief Executive Officer at VaRi Bioscience.

#### **For more Information, Please contact:**

Klaus Nickisch, Ph.D. (CEO): +49 174 1510 148, [knickisch@vari-bioscience.com](mailto:knickisch@vari-bioscience.com)

Kerstin Bode-Greuel, MD, PhD. (Head of BD): +49 170 5265 883, [kbode-greuel@vari-bioscience.com](mailto:kbode-greuel@vari-bioscience.com)

#### **About VaRi Bioscience GmbH**

VaRi Bioscience GmbH is an innovative German biotech company that is pioneering novel approaches to serve high unmet medical needs in various therapeutic areas of Female Health. The company focuses on the discovery, development and commercialization of innovative products centered around its unique, IP-protected approach of novel drug delivery concepts.